论文部分内容阅读
目的观察“宝根1号”方治疗肺脾两虚型小儿反复呼吸道感染(RRTI)的临床疗效及其作用机制。方法将120例肺脾两虚型RRTI患儿随机分为治疗组和对照组(每组60例),分别给予“宝根1号”方和匹多莫德口服液治疗,疗程8周。观察两组临床疗效、治疗前后免疫球蛋白和T细胞亚群的变化。结果治疗组总有效率为91.67%,对照组为66.67%;治疗组疗效优于对照组(P<0.01)。治疗后,两组Ig G、Ig A、Ig M含量较治疗前有所增加(P<0.05,P<0.01),治疗组Ig G、Ig A、Ig M含量高于对照组(P<0.01);治疗组CD3+、CD4+、CD8+较治疗前明显升高(P<0.01),治疗组CD3+、CD4+明显高于对照组(P<0.01)。结论 “宝根1号”方能改善RRTI患儿体液免疫和细胞免疫,治疗肺脾两虚型RRTI疗效良好。
Objective To observe the clinical efficacy and mechanism of “Bao-Gen-1” prescription in treating children with recurrent respiratory tract infection of lung and spleen type (RRTI). Methods One hundred and twenty patients with RRTI of lung and spleen deficiency type were randomly divided into treatment group and control group (60 cases in each group), which were treated with “BaoGan No.1” and Pidotimod respectively for 8 weeks. The clinical curative effect, changes of immunoglobulin and T cell subsets before and after treatment were observed. Results The total effective rate was 91.67% in the treatment group and 66.67% in the control group. The curative effect in the treatment group was better than that in the control group (P <0.01). After treatment, the levels of Ig G, Ig A and Ig M in the two groups increased compared with those before treatment (P <0.05, P <0.01), and the contents of Ig G, Ig A and Ig M in the treatment group were higher than those in the control group ; The levels of CD3 +, CD4 + and CD8 + in the treatment group were significantly higher than those before treatment (P <0.01). The levels of CD3 + and CD4 + in the treatment group were significantly higher than those in the control group (P <0.01). Conclusion “Bao-Gen-1” can improve the humoral and cellular immunity of RRTI children and treat RRTI of lung-spleen deficiency type well.